• Oren Fruchter, Bayya Abed El Raouf, Milton Saute, Elchanan Bruckheimer, Nader Abdel Rachman, and Leonardo Fuks.
• Chest. 2014 Mar 1;145(3 Suppl):497A.

Session TitleBronchoscopy & Interventional ProceduresSESSION TYPE: Slide PresentationsPRESENTED ON: Monday, March 24, 2014 at 09:00 AM - 10:30 AMPURPOSE: The development of Broncho-pleural fistula (BPF) is associated with high rate of morbidity and mortality. We have developed a minimally invasive method of bronchoscopic closure of BPF using Amplazer devices (AD) and Amplazer vascular plugs (AVP), with excellent short-term results. The aim of the present report was to explore the long term outcome of patients and the durability of this novel modality of BPF treatment.MethodsA total of 31 central BPF in 31 patients (mean age 66.8 years, range 19-91) were sealed under moderate sedation bronchoscopically by either AD (N = 19) or AVP (N = 12). The average follow-up period was 17.6 months (range 1-68 months)ResultsThe main etiology for BPF was surgery (N = 24), pneumonectomy (N =14) or lobectomy/segmentectomy (N = 10). The underlying disease was lung cancer either primary (N = 20) or metastatic (n = 2). The immediate success rate was 96% as symptoms related to BPF disappeared in 30/31 of the patients. Short-term (less than 30 days) mortality was 4/31 (13%). At follow-up, 14 patients (45%) are still alive. Out of 12 patients with late mortality, in 5 patients (41 %) the death was directly related to cancer relapse, and no patient died due to BPF recurrence.ConclusionsConclusion: Endobronchial closure of BPF using both types of Amplatzer occluders (AD, AVP) is a minimally invasive effective modality of treatment with high safety profile and satisfactory long term outcome considering the poor prognosis in this particular group of patientsClinical ImplicationsOur work can help other physicians to consider Amplatzer occluders as a safe and effective modality of treatment in a poor prognosis group of patients and bring to crucial therapeutic decisions.DisclosureThe following authors have nothing to disclose: Oren Fruchter, Bayya Abed El Raouf, Milton Saute, Elchanan Bruckheimer, Nader Abdel Rachman, Leonardo Fuks, Mordechai KramerNo Product/Research Disclosure Information.

22 keywords...

hide…